Status:
COMPLETED
Bioinformation Therapy for Lung Cancer
Lead Sponsor:
Fuda Cancer Hospital, Guangzhou
Collaborating Sponsors:
Shengxin Biotechnology Institute, Beijing
Conditions:
Small-cell Lung Cancer
Eligibility:
All Genders
20-80 years
Phase:
PHASE2
PHASE3
Brief Summary
The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable lung cancer.
Detailed Description
By enrolling patients with unresectable lung cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitat...
Eligibility Criteria
Inclusion
- All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies
- Body tumor 1-6, with at least one tumor length \> 2 cm
- KPS ≥ 70, lifespan \> 6 months
- Platelet count ≥ 80×109/L，white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L
Exclusion
- Patients with cardiac pacemaker
- Patients with brain metastasis
- Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction
Key Trial Info
Start Date :
September 2 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 2 2018
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03239171
Start Date
September 2 2017
End Date
September 2 2018
Last Update
January 25 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuda cancer institute of Fuda cancer hospital
Guangzhou, Guangdong, China, 510665